

Non-Neoplastic Disorders of Bone Marrow

*AFIP Atlases of
Tumor and
Non-Tumor Pathology*



AMERICAN REGISTRY
OF PATHOLOGY
Publication & Education

ARP PRESS
Arlington, Virginia

Managing Director of Publications: Heidi Guerrero
Editorial Director: Elizabeth Tomlinson
Production Editor: Dian S. Thomas
Copyeditor: Technica Editorial Services

American Registry of Pathology
Arlington, Virginia 22203
www.arppress.org
ISBN 978-1-933477-66-4

Copyright © 2026 The American Registry of Pathology

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means without the written permission of the publisher. This includes electronic, mechanical, photocopy, recording, or any other information storage and retrieval system.

AFIP ATLASES OF TUMOR AND NON-TUMOR PATHOLOGY

Fifth Series
Fascicle 26

NON-NEOPLASTIC DISORDERS OF BONE MARROW

by

Elizabeth L. Courville, MD

Associate Professor, Department of Pathology
University of Virginia School of Medicine
UVA Health Medical Center
Charlottesville, Virginia

Michael A. Linden, MD, PhD

Richard D. Brunning Professor
Department of Laboratory Medicine and Pathology
University of Minnesota
Minneapolis, Minnesota

Robert P. Hasserjian, MD

Professor of Pathology
Massachusetts General Hospital
Boston, Massachusetts

Published by the
American Registry of Pathology
Arlington, Virginia
2026

AFIP ATLASES OF TUMOR AND NON-TUMOR PATHOLOGY

EDITOR

Jason L. Hornick, MD, PhD

Professor of Pathology, Harvard Medical School
Director of Surgical Pathology and Immunohistochemistry
Brigham and Women's Hospital
Boston, Massachusetts

EDITORIAL ADVISORY BOARD

Laura C. Collins, MBBS	Beth Israel Deaconess Medical Center Boston, Massachusetts
Toby C. Cornish, MD, PhD	University of Colorado School of Medicine Aurora, Colorado
Cristina Magi-Galluzzi, MD, PhD	University of Alabama Birmingham, Alabama
Robert P. Hasserjian, MD	Massachusetts General Hospital Boston, Massachusetts
Arie Perry, MD	University of California San Francisco, California
Lynette M. Sholl, MD	Brigham and Women's Hospital Boston, Massachusetts
Tomas Slavik, MBChB, FCPATH(SA), MMed	Ampath Pathology Laboratories Pretoria, South Africa
Rhonda K. Yantiss, MD	University of Miami Miller School of Medicine Miami, Florida
Matthew M. Yeh, MD, PhD	University of Washington Seattle, Washington



DEDICATIONS

To Mom and Dad, who met working at the Passavant Hospital Hematology Laboratory, thank you for a lifetime of love and support.

Elizabeth L. Courville, MD

To Dr. Robert McKenna, for his extraordinary mentorship, and to Marc Schulte, for his unwavering support on the home front.

Michael A. Linden, MD, PhD

To Nancy Lee Harris, for being an inspiring example of clinical excellence, professionalism, and the advancement of our field through communication and cooperation.

Robert P. Hasserjian, MD



ACKNOWLEDGEMENTS

The authors gratefully acknowledge the colleagues, fellows, and residents from the Departments of Pathology and Laboratory Medicine at the University of Virginia, the University of Minnesota, and Massachusetts General Hospital. Their insights, diagnostic discussions, and daily commitment to patient care have directly informed the clarity and completeness of this work.

We would also like to recognize the many individuals who contributed photomicrographs and illustrative material of these often rare entities; these contributions are cited throughout the figure legends. The technical expertise of our laboratory partners, whose diligence ensures high-quality specimens and images, has similarly strengthened this fascicle.

Finally, we are deeply appreciative of the longstanding tradition of excellence established by the American Registry of Pathology and the Armed Forces Institute of Pathology (ARP/AFIP) and the authors of prior Fascicles, whose scholarship continues to guide and inspire the production of these volumes.

Elizabeth L. Courville, MD
Michael A. Linden, MD, PhD
Robert P. Hasserjian, MD

EDITOR'S NOTE

The Atlases of Tumor Pathology have a long and distinguished history. They were first conceived at a cancer research meeting held in St. Louis in September 1947, as an attempt to standardize the nomenclature of neoplastic diseases. The first series was sponsored by the National Academy of Sciences-National Research Council. The organization of this formidable effort was entrusted to the Subcommittee on Oncology of the Committee on Pathology, and Dr. Arthur Purdy Stout was the first editor-in-chief. Many of the illustrations were provided by the Medical Illustration Service of the Armed Forces Institute of Pathology (AFIP), the type was set by the Government Printing Office, and the final printing was done at the Armed Forces Institute of Pathology. The American Registry of Pathology (ARP) purchased the Fascicles from the Government Printing Office and sold them virtually at cost. Over a period of 20 years, approximately 15,000 copies each of nearly 40 Fascicles were produced. The worldwide impact of these publications over the years has largely surpassed the original goal. They quickly became among the most influential publications on tumor pathology, primarily because of their overall high quality, but also because their low cost made them easily accessible the world over to pathologists and other students of oncology.

Upon completion of the first series, the National Academy of Sciences-National Research Council handed further pursuit of the project over to the newly created Universities Associated for Research and Education in Pathology (UAREP). The Second Series was started, generously supported by grants from the AFIP, the National Cancer Institute, and the American Cancer Society. Dr. Harlan I. Firminger became the editor-in-chief and was succeeded by Dr. William H. Hartmann. The Second Series Fascicles were produced as bound volumes instead of loose leaflets. They featured a more comprehensive coverage of the subjects, to the extent that the Fascicles could no longer be regarded as "atlases" but rather as monographs describing and illustrating in detail the tumors and tumor-like conditions of the various organs and systems.

Dr. Juan Rosai was appointed as editor-in-chief of the Third Series, and Dr. Leslie Sobin became associate editor. A distinguished Editorial Advisory Board was also convened, and these outstanding pathologists and educators played a major role in the success of this series, the first publication of which appeared in 1991 and the last (number 32) in 2003.

The same organizational framework applied to the Fourth Series, meticulously edited by Dr. Steven Silverberg with Dr. Ronald DeLellis as the associate editor. With UAREP and AFIP no longer functioning, ARP remained the responsible organization. The Fourth Series volumes were hardbound with illustrations almost exclusively in color. There was also an increased emphasis on the cytopathologic (intraoperative, exfoliative, or fine needle aspiration) and molecular features that are important

in diagnosis and prognosis. At the time of the Fourth Series, ARP also produced Atlases of Non-Tumor Pathology; these volumes were numbered separately from the tumor volumes.

As in the prior series, the goal of the Fifth Series includes a continuous attempt to correlate, whenever possible, the nomenclature used in the Fascicles with that proposed by the World Health Organization Classification of Tumors, as well as to ensure a consistency of style. Including molecular diagnostics is more important than ever, as is the availability of an online component, a more nimble website (www.arppress.org), and a social media presence. Now in this series, the tumor and non-tumor volumes are combined and consecutively numbered as the Atlases of Tumor and Non-Tumor Pathology. Close cooperation between the various authors and their respective liaisons from the Editorial Board will continue to be emphasized in order to minimize unnecessary repetition and discrepancies in the text and illustrations.

Particular thanks are due to the members of the Editorial Advisory Board, our reviewers, the editorial and production staff, and the individual Fascicle authors for their ongoing efforts to ensure that this series is a worthy successor to the previous four.

Jason L. Hornick, MD, PhD



PREFACE

This Fascicle, *Non-Neoplastic Disorders of Bone Marrow*, is devoted to the evaluation and interpretation of bone marrow and peripheral blood specimens from both adult and pediatric patients. The primary focus of this volume is the spectrum of acquired non-neoplastic processes that affect the blood and marrow. We also include selected clonal non-neoplastic conditions as well as germline or congenital conditions that affect the blood and bone marrow. Neoplasms are discussed when they form an essential part of the differential diagnosis. Key concepts and comparisons are highlighted through frequent summary tables designed to emphasize important morphologic, immunophenotypic, genetic, and clinical features of these disorders, which can often mimic malignant conditions.

The Fascicle is organized into ten chapters. The first three chapters provide foundational material: an overview of normal bone marrow and peripheral blood, guidance on marrow collection and processing, and a discussion of sample adequacy and artifact. In chapter 2, we provide a practical approach to bone marrow and blood evaluation. The remaining chapters are organized by etiology rather than specific blood or bone marrow cell type, since many conditions that affect the hematopoietic system manifest in a myriad of cell types in the blood and/or marrow. Chapters 4 through 8 address these distinct etiologies: paraneoplastic phenomena, autoimmune diseases, metabolic disorders, nutritional deficiencies, and the effects of toxins and medications. The last two chapters are devoted to clonal and congenital disorders that have blood and marrow manifestations.

To facilitate linking specific pathologic findings in blood or bone marrow to the discussions of their differential diagnoses, we have included two comprehensive cross-referencing tables in this preface. Table 1 lists bone marrow features (such as fibrosis, changes in cellularity, dysplasia) and the relevant chapters where they are discussed, while Table 2 similarly lists specific peripheral blood findings (e.g., neutropenia, inclusions, circulating blasts). For ease of use, the relevant chapter for each differential diagnosis is provided, enabling readers to move efficiently between patterns of abnormality and the potential diagnoses that may explain these findings.

Our goal in assembling this Fascicle is to offer a practical, morphologically-grounded resource for practicing pathologists and hematopathologists, trainees, and all clinicians who rely on blood and marrow examination in patient care. Non-neoplastic disorders of the bone marrow frequently require the integration of subtle morphologic clues with the clinical context and laboratory data; pathologists also must know what confirmatory ancillary tests to order (and which scenarios require testing). The illustrations and tables in this volume support an integrative approach and serve as a useful reference in both routine practice and complex diagnostic evaluations.

Importantly, these non-neoplastic disorders can mimic malignant hematologic conditions, potentially leading to misdiagnosis and the administration of inappropriate therapy. Hematopathology training curricula and educational resources tend to focus more on hematologic malignancies, and thus, trainees and practicing pathologists are often less comfortable when confronted with the differential diagnosis of a benign hematologic process. We hope this Fascicle fills this gap by illustrating the distinct morphologic characteristics and practical approach to the broad spectrum of benign blood and bone marrow disorders.

Elizabeth L. Courville, MD
Michael A. Linden, MD, PhD
Robert P. Hasserjian, MD



Finding	Associated Conditions	Chapter Discussed
General Bone Marrow Findings		
Hypercellularity	Very non-specific: can be seen in a variety of non-neoplastic conditions including marrow regeneration, drug effect, nutritional deficiency, infection, autoimmune processes, paraneoplastic conditions, and congenital conditions	Multiple
Hypocellularity	Infections	4
	Aplastic anemia	5, 6
	Systemic lupus erythematosus	6
	Copper deficiency	7
	Alcohol toxicity, chronic benzene exposure	8
	Graft versus host disease (GVHD)	8
	Cytotoxic therapies (methotrexate and other cytotoxic agents)	8
	TNF α -inhibitors	8
	Paroxysmal nocturnal hemoglobinuria (PNH)	9
	Germline conditions, including Fanconi anemia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome, germline mutations in RUNX1, congenital amegakaryocytic thrombocytopenia	10
Fibrosis	Felty syndrome	6
	Systemic lupus erythematosus	6
	Autoimmune myelofibrosis	6
	TAFRO syndrome	6
	Renal osteodystrophy (paratrabecular fibrosis)	7
	Post-stem cell transplant for advanced fibrotic myeloproliferative neoplasm	8
	Chronic benzene exposure	8
	Thrombopoietin receptor agonists (TPO mimetics)	8
Amorphous material	Bone crush artifact	3
	Serous atrophy, edema (interstitial amorphous material)	7
	Chemoablation	8
Necrosis	Infection (mycobacterium tuberculosis, coxiella)	4
	Hemophagocytic lymphohistiocytosis	4
	Granulocyte-colony stimulating factor (G-CSF)	8
	Sickle cell disease	10
Myeloid Precursors		
Vacuoles	Copper deficiency	7
	VEXAS syndrome	9
Granulocytic left-shift	Infection	4
	Felty's syndrome	6
	Copper deficiency	7
	Granulocyte-colony stimulating factor (G-CSF)	8
	Marrow recovery	8
Granulocytic maturation arrest	Infection	4
	Levamisole exposure	8
	Medications (trimethoprim and sulfamethoxazole [Bactrim], ticlopidine, busulfan, methamizole, ethosuximide, and chlorpromazine)	8
	Cyclic neutropenia, Chediak-Higashi syndrome, severe congenital neutropenia	10
Granulocytic hyperplasia	Infection	4
	Felty's syndrome	6
	Paraneoplastic leukemoid reaction	7
	Granulocyte-colony stimulating factor (G-CSF)	8

Table 1, continued

Finding	Associated Conditions	Chapter Discussed
Hypergranularity (retained primary granules)	Infection	4
	Granulocyte-colony stimulating factor (G-CSF)	8
Giant band forms	Megaloblastic anemia (nutritional)	7
	Medication (methotrexate, 5-fluorouracil, hydroxyurea)	8
Dysplasia (hypogranular/abnormal segmentation)	Medication (tacrolimus, mycophenylate mofetil)	8
	Post-chemotherapy	8
	Dyskeratosis congenita, Shwachman-Diamond syndrome, severe congenital neutropenia	10
Eosinophilia	Paraneoplastic eosinophilia/hypereosinophilia	7
	Lymphocytic variant of hypereosinophilic syndrome	9
	Infection	4
Increased Blasts (typically mild increase)	Infection	4
	Medication (G-CSF, romiplostim)	8
	Marrow recovery	8
Megakaryocytes		
Abnormal morphology	HIV (scant cytoplasm, hyperchromatic nuclei)	4
	Germline conditions (Table 10-7)	10
	Drug/medication (Table 8-1)	8
	POEMS	5
Increased/Decreased in number	HIV (increased megakaryocytes)	4
	POEMS (increased megakaryocytes)	5
	Congenital amegakaryocytic thrombocytopenia, thrombocytopenia with absent radii syndrome (decreased megakaryocytes)	10
	Immune thrombocytopenic purpura (increased megakaryocytes)	6
	Aplastic anemia (decreased megakaryocytes)	6
Clustering	Marrow regeneration following chemotherapy	8
	Immune thrombocytopenic purpura	6
	POEMS	5
Plasma Cells		
Polytypic plasmacytosis	Non-specific	1
	Infection (various, including HIV)	4
Minor clonal population	Monoclonal gammopathy of undetermined significance (MGUS)	9
Immunoglobulin inclusions/pseudo-inclusions (Russell bodies, Mott cells, Dutcher bodies)	Non-specific	1
Lymphocytes		
Lymphoid aggregates	Normal component	1
	Infection	4
	Autoimmune/immune mediated	5,6
Minor clonal lymphocyte population	Monoclonal B cell lymphocytosis	9
	T-cell clone of uncertain significance	9
Hematogones	Normal component	1
	Hyperplasia following stem cell transplant or chemotherapy	8
Erythroid Precursors		
Hyperplasia	Autoimmune hemolytic anemia	5
	Copper deficiency	7
	Alcohol toxicity	8

Table 1, continued

Finding	Associated Conditions	Chapter Discussed
Hyperplasia (cont.)	Medication (including hypomethylating agents, arsenic trioxide, erythropoietin)	8
	Paroxysmal nocturnal hemoglobinuria	9
	Sickle cell disease	10
	Congenital disease (thalassemia, congenital dyserythropoietic anemia, Fanconi anemia)	10
Ring sideroblasts	HIV	4
	Copper deficiency	7
	Alcohol toxicity	8
	Medication (including isoniazid, chloramphenicol, linezolid, penicillamine, and triethylene tetramine dihydrochloride)	8
	Congenital disease (thalassemia, congenital sideroblastic anemia)	10
Dysplasia	Non-specific finding seen as marrow response to anemia, in nutritional deficiency, and in germline conditions, among others	?
Erythroid cytoplasmic vacuoles	Copper deficiency	7
	Chronic alcohol exposure	8
	VEXAS	9
Pure red cell aplasia	Infection (including parvovirus B19)	4
	Variety of secondary causes including lymphoproliferative disorders, thymoma	6
Maturation arrest	Parvovirus B19	4
Megaloblastic change	Copper deficiency; Vitamin B12/folate deficiency	7
	Alcohol toxicity	8
	Medications	8
Abnormal Histiocytes		
Histiocytes with inclusions	Infections	4
	Congenital metabolic conditions	10
Histiocytes with vacuoles	Congenital metabolic conditions	10
	Non-specific finding	
Hemophagocytosis	Infections, especially EBV	4
	Paraneoplastic, especially EBV+ lymphomas	7
	Congenital/familial causes	10
	Drug-induced	8
Histiocytes with crystals	Paraneoplastic (crystal-storing histiocytosis)	7
	Cystinosis	10
Granulomas	Infections	4
	Sarcoidosis	
	Non-specific finding	

Table 2
ABNORMAL PERIPHERAL BLOOD FINDINGS AND
POTENTIAL NON-NEOPLASTIC ASSOCIATIONS/CAUSES

Finding	Associated Conditions	Chapter Discussed
White Blood Cells		
Neutrophilia	Asplenia	1
	Infection	4
	Paraneoplastic leukemoid reaction	5
	CVID (mild neutrophilia)	6
	Medication (G-CSF, GM-CSF, glucocorticoids, lithium)	8
Neutropenia	Paraneoplastic (immune mediated)	5
	Autoimmune	6
	Copper deficiency	7
	Medication effect (various)	8
	Levamisole exposure	8
	Leukocyte protein abnormalities (Duffy-null associated neutrophil count, cyclic neutropenia, Chediak-Higashi Syndrome)	10
	Germline conditions (including severe congenital neutropenia, Shwachman-Diamond syndrome, GATA2 deficiency syndrome)	10
Vacuoles	Monocytes (occasional vacuoles): normal	1
	Neutrophils: Infection	4
	Any leukocyte: Jordan's anomaly	10
	Lymphocytes: sialidosis	10
	Excess EDTA exposure	
Inclusions	Monocytes (morulae, erlichiosis)	4
	Granulocytes (morulae, erlichiosis and anaplasmosis)	4
	Granulocytes/monocytes: MYH9-related disorders	10
Microorganisms in neutrophils or monocytes	Infections	4
Döhle bodies	Infection	4
	Paraneoplastic	5
	Hematopoietic growth factors/G-CSF	8
Myeloid left-shift	Marrow involvement by metastatic disease	3
	Infection	4
	Marrow recovery after therapy	8
	Hematopoietic growth factors/G-CSF	8
Hypogranulation	Poor staining quality	3
Abnormal granulation	Alder-Reilly anomaly	10
	Chediak-Higashi	10
Toxic granulation	Infection	4
	Paraneoplastic reaction	5
	Hematopoietic growth factors/G-CSF	8
Hypersegmentation	Megaloblastic anemia (nutritional)	7
	Medication (methotrexate, 5-fluorouracil, hydroxyurea)	8
Hyposegmentation	Medication (tacrolimus, mycophenylate mofetil)	8
	Pelger-Huët anomaly/syndrome	10
Eosinophilia	Infection	4
	Paraneoplastic hypereosinophilia	5
	Castleman/TAFRO syndrome	6
	Medication (penicillins, sulfa drugs, allopurinol, diphenylhydantoin)	8
	Medication (DRESS syndrome)	8
	Lymphocytic variant of hypereosinophilic syndrome	9

Table 2, continued

Finding	Associated Conditions	Chapter Discussed
Circulating blasts (in low numbers)	Medication (G-CSF, romiplostim)	8
	Marrow recovery	8
	As component of myeloid left-shift (see separate listing)	
	Down Syndrome/Transient Abnormal Myelopoiesis (may moderate or high blast percentage)	10
Lymphocytosis	Transient stress lymphocytosis in patients with emergency medical conditions	1
	Infection, commonly viral and occasionally bacterial	4
	Castleman/TAFRO	6
	Polyclonal B lymphocytosis	6
	Post-stem cell transplant (large granular lymphocytes)	8
	Dasatinib therapy (large granular lymphocytes)	8
	Monoclonal B cell lymphocytosis	9
Atypical/abnormal appearing lymphocytes	Infection, may be striking with infectious mononucleosis	4
	CAR-T therapy	8
Basophilia	Filarial infections, rarely viral and mycobacterial infections	4
Monocytosis	Asplenia	1
	Infection	4
	CVID	6
	Marrow recovery after therapy	8
	Hematopoietic growth factors/G-CSF	8
Plasma cells	Viral infections	4
Platelets		
Thrombocytosis	Asplenia	1
	Infection	4
	Paraneoplastic	5
	Chronic inflammatory state (acute phase reactant)	1
	Iron deficiency	7
Thrombocytopenia	Pseudothrombocytopenia	1
	Marrow involvement by metastatic disease	3
	Infection	4
	Autoimmune/Immune Mediated	5, 6
	Nutritional Deficiency	7
	Toxins/Drugs	8
	Germline conditions (including mutations in RUNX1, ANKRD26, ETV6; SAMD9/SAMD9L disorders; congenital megakaryocytic thrombocytopenia; thrombocytopenia with absent radii syndrome)	10
	Storage Disorders	10
Small platelets	Wiskott-Aldrich syndrome	10
Large platelets	MYH9-related disorders	10
	Platelet-type vWBD	10
	Hermansky-Pudlak syndrome	10
Platelet granulation abnormalities	Hermansky-Pudlak syndrome (pale)	10
	Grey-platelet syndrome (pale)	10
	Chediak-Higashi syndrome (hypergranulated)	10
Extrinsic Elements in Blood		
Megakaryocytes	Rarely seen in normal	1
Endothelial cells	Rarely seen in normal	1
Parasites	Infections	4

Table 2, continued

Finding	Associated Conditions	Chapter Discussed
Red Blood Cells		
Microorganisms	Infections	4
Erythrocytosis/ polycythemia	TEMPI syndrome	4
	POEMS syndrome	4
	Drugs/Medications	8
	Hypoxia	
Nucleated red blood cells (nRBC)	Asplenia	1
	Leukoerythroblastic blood picture due to carcinoma (chap. 1) some drugs (chap. 8), or (rarely) autoimmune myelofibrosis (chap. 6)	1, 8, 6
	Normal in neonates	1
Increased poikilocytosis	Nonspecific finding, can be seen in asplenia, iron deficiency, hemo- globinopathy, and hemolysis, among other causes; RBC poikilo- cyte shape(s) can provide clues to the physiologic/disease state	1
Basophilic stippling	Lead poisoning (coarse stippling)	8
	Thalassemia/hemoglobinopathy (fine stippling)	10
	Congenital dyserythropoietic anemia	10

Permission to use copyrighted material has been granted by:

American Society of Hematology

Used with permission of the American Society of Hematology. These images were originally published in ASH Image Bank. With permission conveyed through Copyright Clearance Center, Inc.

Kaur G, Vishwanathan GK, Khan MV. Pseudogaucher cell in chronic myeloid leukaemia. ASH Image Bank. 2020; image 63315. For figure 10-2.

Scordino T. Hemoglobin C crystals and target cells. ASH Image Bank. 2015; image 60269. For figure 10-12B.

Calvo K. Disorders of iron metabolism and heme. ASH Image Bank. 2015; image 00060064. For figure 10-26A.

CONTENTS

1. Normal Bone Marrow and Peripheral Blood.....	1
Architecture and Cellularity	1
Cellular Elements	3
Nonhematopoietic Elements	3
Mature Lymphocytes/Plasma Cells.....	11
Normal B-Lineage Precursors/Hematogones.....	13
Erythropoiesis.....	20
Myelopoiesis and Monopoiesis.....	29
Megakaryocytes.....	34
Mast Cells	38
Peripheral Blood.....	39
Special Considerations in Fetal Hematopoiesis	46
2. Bone Marrow Collection, Processing, and Evaluation.....	51
Specimen Procurement	51
Bone Marrow Aspiration	51
Aspirate Collection for Ancillary Studies	51
Bone Marrow Biopsy and Clot Section	53
Specimen Processing.....	53
Postmortem Considerations	54
Bone Marrow Evaluation	55
Aspirate Smear Evaluation	55
Core Biopsy and Clot Section Evaluation.....	59
Peripheral Blood Evaluation	60
Bone Marrow Reporting.....	64
3. Bone Marrow Adequacy, Artifacts, and Involvement by Metastatic Disease.....	67
Adequacy and Artifacts	67
Involvement by Metastatic Disease	70
4. Infections.....	77
General Patterns of Bone Marrow and Blood Reaction to Systemic Infections	77
Hyperplasia and Leukemoid Reaction	77
Hypoplasia.....	80
Morphologic Dysplasia	81
Lymphoid Aggregates.....	81
Granulomas.....	83
Plasmacytosis.....	85
Hemophagocytosis.....	87
Peripheral Blood Lymphocytosis	91

Viral Infections.....	93
Parvovirus B19 Infection.....	93
HIV Infection	94
EBV Infection	97
CMV Infection	99
Dengue Fever.....	99
COVID-19 Infection.....	100
Virus-Associated Aplastic Anemia	101
Bacterial Infections	103
Brucellosis.....	103
Rickettsial Infection	103
Relapsing Fever (Borreliosis)	103
Mycobacterial Infection	104
Whipple Disease.....	106
Ehrlichiosis and Anaplasmosis.....	106
Fungal Infections	108
Cryptococcosis	108
Histoplasmosis	109
Parasites.....	110
Leishmaniasis	110
Toxoplasmosis	112
Trypanosomiasis.....	112
Filariasis.....	114
Malaria.....	114
Babesiosis.....	118
5. Paraneoplastic Syndromes.....	127
Paraneoplastic Hematologic Syndromes Associated with Abnormal Blood Counts	127
Paraneoplastic Leukemoid Reaction.....	127
Paraneoplastic Eosinophilia.....	130
Paraneoplastic Thrombocytosis.....	130
Paraneoplastic Autoimmune Cytopenias.....	132
Autoimmune Hemolytic Anemia	132
Immune Thrombocytopenia	134
Autoimmune Neutropenia	134
Evans Syndrome.....	134
Pure Red Cell Aplasia/Aplastic Anemia	134
Paraneoplastic Syndromes Associated with Plasma Cell Neoplasms	134
POEMS Syndrome	134
TEMPI Syndrome	137
Crystal-Storing Histiocytosis.....	137
Cryoglobulinemia	139

6.	Autoimmune and Immune-Mediated Conditions	143
	Aplastic Anemia	143
	Pure Red Cell Aplasia	143
	Autoimmune Hemolytic Anemia	145
	Thrombotic Thrombocytopenic Purpura	149
	Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura)	149
	Autoimmune Agranulocytosis	151
	Felty Syndrome	152
	Systemic Lupus Erythematosus	152
	Autoimmune Myelofibrosis	155
	Castleman Disease and Tafro Syndrome	155
	Common Variable Immune Deficiency	155
	Polyclonal B Lymphocytosis	158
7.	Nutritional Deficiencies and Acquired Metabolic Disorders	163
	Iron Deficiency	163
	Copper Deficiency	166
	Vitamin B12 and Folate Deficiencies (Megaloblastic Anemia)	166
	Gelatinous Transformation or Serous Atrophy	171
	Renal Osteodystrophy	177
	Acquired Metabolic Disturbances Reflected in the Peripheral Blood	177
8.	Drug and Toxin Effects on Bone Marrow	183
	Toxins Affecting the Bone Marrow	183
	Alcohol	183
	Chemical and Environmental Exposures	185
	Drugs Secondarily Affecting the Bone Marrow	187
	Drugs Globally Affecting the Bone Marrow	187
	Drugs Affecting Erythropoiesis	192
	Drugs Affecting Thrombopoiesis	194
	Drugs Affecting Granulopoiesis	194
	Drugs Affecting Lymphocytes	197
	Agents Used to Treat Myeloid Neoplasms	199
	Intensive Chemotherapy	199
	Arsenic and All-Trans-Retinoic Acid (ATRA) Therapy for Acute Promyelocytic Leukemia	204
	Stem Cell Transplantation Considerations	204
	Drugs Stimulating Hematopoiesis	211
	Erythropoietin	211
	Granulocyte Colony-Stimulating Factor	211
	Thrombopoietin Mimetics	214
9.	Clonal Nonmalignant Conditions	223
	Clonal Myeloid Proliferations	224

Clonal Hematopoiesis of Indeterminate Potential	224
Clonal Cytopenias of Undetermined Significance	227
Paroxysmal Nocturnal Hemoglobinuria	229
VEXAS Syndrome.....	230
Clonal Lymphoid Populations	232
Monoclonal B-Cell Lymphocytosis	232
T-Cell Clones of Uncertain Significance.....	234
Lymphocytic Variant of Hypereosinophilic Syndrome	237
Non-Immunoglobulin M-Type Monoclonal Gammopathy of Undetermined Significance.....	238
IgM-Type Monoclonal Gammopathy of Undetermined Significance	238
Cold Agglutinin Disease	242
10. Congenital Conditions.....	245
Inborn Errors of Metabolism/Storage Diseases	245
Familial Hemophagocytic Lymphohistiocytosis	250
Red Cell Protein Abnormalities.....	251
Sickle Cell Disease	251
Hemoglobin C Disease	254
Hemoglobin E Disease.....	254
Thalassemias.....	255
Glucose-6-Phosphate Dehydrogenase Deficiency.....	259
Sideroblastic Anemia.....	261
Congenital Dyserythropoietic Anemia	262
Disorders of Red Cell Cytoskeleton	263
Leukocyte Protein Abnormalities.....	264
Duffy-Null-Associated Neutrophil Count (Benign Ethnic Neutropenia)	264
Cyclic Neutropenia	266
Pelger-Huët Syndrome	266
Chediak-Higashi Syndrome	266
MYH9-Related Disorders	267
Warts, Hypogammaglobulinemia, Immune Deficiency, and Myelokathexis (WHIM) Syndrome and Myelokathexis	268
Platelet Protein Abnormalities	269
Germline Conditions Affecting Hematopoiesis	272
Down Syndrome (Trisomy 21)	273
Germline Conditions Associated Predominantly with Anemia.....	274
Germline Conditions Associated Predominantly with Neutropenia or Monocytopenia.....	277
Germline Conditions Associated Predominantly with Thrombocytopenia.....	280
Other Germline Predisposition Disorders	283
Index	289